Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Eur Rev Med Pharmacol Sci ; 28(9): 3455-3462, 2024 May.
Article in English | MEDLINE | ID: mdl-38766798

ABSTRACT

OBJECTIVE: Our study aims to determine the frequency and types of GTD (Gestational Trophoblastic Disease) in our clinic, to evaluate its relationship with clinical parameters, and the consistency of clinical prediagnosis and pathological definitive diagnosis. PATIENTS AND METHODS: In the present study, hospital records of 120 patients with gestational trophoblastic disease between January 2019 and August 2022 were obtained and evaluated retrospectively. Demographic, hematological, biochemical, and clinical data were collected in detail, and the data were analyzed statistically. RESULTS: Our study included a total of 120 female patients, with an average age of 31.16±9.70. The average number of patients was 3. The average time for women to receive the diagnosis was 9.80±2.45 weeks, with the most frequent complaint on our part being bleeding (85.8%). When the pathology outcomes of the patients we included in our study were examined, it was found that the number of patients diagnosed with incomplete abortion was 34, the number of patients diagnosed with complete abortion was 82, the number of invasive moles diagnosed was 3, and the number of patient diagnosed with choriocarcinoma was 1. Kappa ratio was calculated as 0.419 (p<0.001) when the compliance of the clinical diagnosis was assessed. This value was consistent with median level alignment. In a study that examined the three years of our calism in our bulk, 1.8 per 1,000 births were followed frequently. CONCLUSIONS: We should inform patients in detail about gestational trophoblastic diseases and warn patients not to delay their consequences. We should recommend that pregnancy be avoided for 12 months for low-risk patients and 18 months for high-risk patients after GTD.


Subject(s)
Gestational Trophoblastic Disease , Humans , Female , Gestational Trophoblastic Disease/diagnostic imaging , Gestational Trophoblastic Disease/diagnosis , Pregnancy , Retrospective Studies , Adult , Young Adult
2.
Eur Radiol ; 8(8): 1422-4, 1998.
Article in English | MEDLINE | ID: mdl-9853228

ABSTRACT

The US, CT, and X-ray findings in a patient with omental fibroma of the lesser omentum are described. Ultrasound showed a solid mass with cystic areas in the central region. At CT the lesion showed peripheral enhancement and central hypodensity. On X-ray studies with barium, there was border distortion in the lesser curvature of the stomach. The mass was resected surgically. A pathologic diagnosis of fibroma was confirmed.


Subject(s)
Fibroma/diagnosis , Omentum/diagnostic imaging , Peritoneal Neoplasms/diagnosis , Tomography, X-Ray Computed , Aged , Female , Fibroma/surgery , Humans , Laparotomy , Omentum/surgery , Peritoneal Neoplasms/surgery , Radiography, Abdominal , Ultrasonography
3.
Nephron ; 78(2): 207-11, 1998.
Article in English | MEDLINE | ID: mdl-9496739

ABSTRACT

Enzymatic antioxidant defense system and antioxidant defense potential (AOP) were studied in kidney tissue from rabbits treated with cyclosporine (CsA, 25 mg/kg/day), antioxidant vitamins (E, 100 mg/kg/day plus C, 200 mg/ kg/day), and CsA plus antioxidant vitamins, and in kidney tissue from control animals. Although no change was observed in superoxide dismutase (SOD) activity, glutathione peroxidase (GSH-Px) and catalase (CAT) activities were found decreased in kidney tissue exposed to CsA for 10 days compared with control tissue. The level of thiobarbituric acid-reagent substances (TBARS) was higher and antioxidant defense potential (AOP) lower in the CsA-treated group compared with the other groups. Histopathological examination reveals important subcellular damage in the renal tissue from the animals treated with CsA. Antioxidant vitamin therapy caused full improvement in the enzyme activities, TBARS levels and AOP, but the subcellular damage was partly ameliorated in the CsA plus vitamin group. Results suggest that CsA impairs the antioxidant defense system and reduces the antioxidant defense potential in the renal tissue. Antioxidant vitamin treatment protects the tissue in part against toxic effects of the drug.


Subject(s)
Antioxidants/metabolism , Cyclosporins/pharmacology , Enzyme Inhibitors/pharmacology , Kidney Diseases/prevention & control , Kidney/drug effects , Kidney/enzymology , Animals , Ascorbic Acid/administration & dosage , Ascorbic Acid/therapeutic use , Catalase/antagonists & inhibitors , Catalase/drug effects , Catalase/metabolism , Cyclosporine , Drug Therapy, Combination , Glutathione Peroxidase/antagonists & inhibitors , Glutathione Peroxidase/drug effects , Glutathione Peroxidase/metabolism , Kidney/pathology , Kidney Diseases/chemically induced , Kidney Glomerulus/cytology , Kidney Glomerulus/drug effects , Kidney Glomerulus/pathology , Malondialdehyde/metabolism , Rabbits , Superoxide Dismutase/antagonists & inhibitors , Superoxide Dismutase/drug effects , Superoxide Dismutase/metabolism , Thiobarbituric Acid Reactive Substances/metabolism , Vitamin E/administration & dosage , Vitamin E/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...